Seagen Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

David Epstein

Chief Executive Officer (CEO)

US$58.6m

Compensación total

Porcentaje del salario del CEO	0.3%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2yrs
Promedio de permanencia en la Junta Directiva	9.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Epstein en comparación con los beneficios de Seagen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-US$649m
Dec 31 2022	US$59m	US$190k	-US$610m

Compensación vs. Mercado: La compensación total de David($USD58.59M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD5.71M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de David con los resultados de la empresa.

CEO

David Epstein (61 yo)

less than a year

Permanencia

US$58,588,196

Compensación

Mr. David R. Epstein, B.Sc., M.B.A., serves as Chief Executive Officer and Director at Seagen Inc. since November 9, 2022. He served as an Independent Director at Senti Biosciences, Inc. since June 09, 202...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Epstein	CEO & Director	less than a year	US$58.59m	sin datos
Todd Simpson	Chief Financial Officer	17.8yrs	US$5.71m	0.063% MX$ 390.5m
Vaughn Himes	Chief Technical Officer	6.9yrs	US$4.54m	0.072% MX$ 445.6m
Jean I. Liu	Chief Legal Officer & Corporate Secretary	8.7yrs	US$5.95m	0.028% MX$ 170.0m
Charles Romp	Executive Vice President of Commercial U.S.	3.3yrs	US$5.03m	0.032% MX$ 193.9m
Roger Dansey	Chief Medical Officer and President of Research & Development	less than a year	US$36.39m	0.014% MX$ 83.8m
William Compton	Senior VP of Global Information Technology & CIO	less than a year	sin datos	sin datos
David Caouette	Vice President of Corporate Communications	no data	sin datos	sin datos
Matt Skelton	Vice President of Marketing	7.7yrs	sin datos	sin datos
Peggy Pinkston	Chief Human Resources Officer	less than a year	sin datos	sin datos
Natasha Hernday	Chief Business Officer	less than a year	sin datos	sin datos
Megan O'Meara	Head of Early Stage Development & VP	no data	sin datos	sin datos

2.0yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SGEN * se considera experimentado (2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Epstein	CEO & Director	less than a year	US$58.59m	sin datos
John Orwin	Independent Director	9.5yrs	US$468.53k	0.015% MX$ 95.2m
David Gryska	Independent Director	18.3yrs	US$483.53k	0.026% MX$ 160.9m
Daniel Welch	Independent Director	16.1yrs	US$468.53k	0.0099% MX$ 61.0m
Felix Baker	Independent Chair of the Board	20yrs	US$528.53k	0.022% MX$ 136.4m
Ted Love	Independent Director	2.9yrs	US$471.03k	0.0025% MX$ 15.5m
Nancy Simonian	Independent Director	11.3yrs	US$474.53k	0.033% MX$ 206.0m
Alpna Seth	Independent Director	5.3yrs	US$471.03k	0.0069% MX$ 42.5m
Sandra Swain	Independent Director	less than a year	US$214.73k	sin datos

9.5yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de SGEN * se considera experimentada (9.5 años de antigüedad promedio).

Seagen Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Second quarter 2022 earnings released: US$0.73 loss per share (vs US$0.47 loss in 2Q 2021)

Seagen Inc. Revises Earnings Guidance for the Year 2022

Insufficient new directors

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Insufficient new directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad